Clinical Trials Browser

Mastocytosis, Systemic × avapritinib × 90 days × Clear all

NCT03580655 2026-04-24

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Phase 2 Completed

107 enrolled 30 charts 1 FDA

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT07255638 2026-04-20

A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany

Mastocytosis, Mastocytosis, Systemic